Technology | Antiplatelet and Anticoagulation Therapies | July 14, 2016

BBMK Technologies Launches ClotMD Mobile App for Real-time Warfarin Management

Application sends real-time alerts on INR levels, scheduled testing and medication reminders to improve patient compliance

BBMK Technologies, ClotMD mobile app, real-time warfarin management

July 14, 2016 — BBMK Technologies recently announced the launch of ClotMD, a cloud-based application and mobile solution. The software-as-a-service (SaaS)-based solution allows healthcare providers to overcome the challenges of managing patients on anticoagulant medication, specifically warfarin.

Healthcare providers can easily manage on-site testing or home INR monitoring while enhancing patient medication adherence and improving their business. With ClotMD, providers have access to a fully integrated warfarin monitoring solution, allowing patients to engage actively in their health for an improved outcome on any computer or mobile device.

Patients who are on warfarin to manage anticoagulation require consistent and ongoing testing of INR levels to maintain within therapeutic range and avoid potentially serious health implications. ClotMD is designed to help healthcare providers manage their warfarin patient population while improving day-to-day business processes. Providers can now focus on patients who require their attention when they fall outside of target therapeutic range or are non-compliant with prescribed medication and/or testing.

The app works on any computer or mobile device, providing a real-time connection between providers and patients. ClotMD allows for convenient management of INR levels, dosing calculations and testing schedules.

The ClotMD mobile app makes patient-centric care possible by delivering real-time alerts on INR levels, scheduled testing and medication reminders.  Further, patients can also receive automatic notifications from their healthcare provider alerting them to a warfarin dosage change. A built-in diet library offers another layer of support for patients who want to be proactive regarding their health. History of current and previous INR levels can be tracked and shared by the patient.

For more information: www.clotmd.com

Related Content

One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 
News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual...
The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart at
The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images

News | Antiplatelet and Anticoagulation Therapies | May 15, 2021
May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in pat
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term,...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal a
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce